/
MRNA
$63.32-$0.33 (-0.52%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$25.4B
399M shares
52-week range
$22.28 – $85.60
65% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-310.54
Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
www.modernatx.com- Employees
- 4,700
- IPO / List date
- Dec 7, 2018
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds MRNA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 881,200 | $44.8M |
| Bridgewater Associatesas of 2026-03-31 | 74,822 | $3.8M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2017-08-03 | 1-for-10reverse |
| 2011-12-23 | 1-for-10reverse |
| 2010-07-22 | 1-for-4reverse |
Recent trades on TradeandTell
- 7/10/2026in July Portfolio →
